Gsap

Gsap does not develop its own therapeutics but provides consulting and operational support for pharmaceutical, biotechnology, medical device, advanced therapies (including cell therapy and CAR-T), digital health companies throughout the product lifecycle. It has supported regulatory submissions for cell therapies and COVID-related products in Israel and internationally. The company has played a key role in helping clients achieve regulatory approvals including FDA/EMA/IMOH certifications. It was instrumental in supporting the first CAR-T submission to Israel’s Ministry of Health on behalf of Sheba Medical Center/Ella Institute. During COVID‑19 it led clinical trial operations for vaccine development in Israel. No proprietary clinical results as it does not own therapeutic assets.